Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perelló A, González X, Jiménez B, Merino M, Palacios P, Pascual T, Alba E, Villanueva L, Chillara S, Ferrero-Cafiero JM, Galvan P, Prat A, Ciruelos E. Pernas S, et al. Among authors: ferrero cafiero jm. NPJ Breast Cancer. 2024 Nov 26;10(1):101. doi: 10.1038/s41523-024-00710-x. NPJ Breast Cancer. 2024. PMID: 39592624 Free PMC article.
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, Martínez-Sáez O, Sánchez-Bayona R, Ferrero-Cafiero JM, Salvador F, Papakonstantinou A, Prat A, Oliveira M, Pascual T. Villacampa G, et al. Among authors: ferrero cafiero jm. JAMA Oncol. 2024 Oct 1;10(10):1331-1341. doi: 10.1001/jamaoncol.2024.3456. JAMA Oncol. 2024. PMID: 39207778
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, Martínez-Sáez O, Cejalvo JM, Margelí M, Tolosa P, Salvador-Bofill FJ, Cruz J, González-Farré B, Sanfeliu E, Òdena A, Serra V, Pardo F, Luna Barrera AM, Arumi M, Guerra JA, Villacampa G, Sánchez-Bayona R, Ciruelos E, Espinosa-Bravo M, Izarzugaza Y, Galván P, Matito J, Pernas S, Vidal M, Santhanagopal A, Sellami D, Esker S, Fan PD, Suto F, Vivancos A, Pascual T, Prat A, Oliveira M. Brasó-Maristany F, et al. Among authors: ferrero cafiero jm. Nat Commun. 2024 Jul 11;15(1):5826. doi: 10.1038/s41467-024-50056-y. Nat Commun. 2024. PMID: 38992028 Free PMC article.
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Oliveira M, Falato C, Cejalvo JM, Vila MM, Tolosa P, Salvador-Bofill FJ, Cruz J, Arumi M, Luna AM, Guerra JA, Vidal M, Martínez-Sáez O, Paré L, González-Farré B, Sanfeliu E, Ciruelos E, Espinosa-Bravo M, Pernas S, Izarzugaza Y, Esker S, Fan PD, Parul P, Santhanagopal A, Sellami D, Villacampa G, Ferrero-Cafiero JM, Pascual T, Prat A. Oliveira M, et al. Among authors: ferrero cafiero jm. Ann Oncol. 2023 Aug;34(8):670-680. doi: 10.1016/j.annonc.2023.05.004. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211044 Free article.
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, Pernas S, Muñoz M, Vidal MJ, Margelí Vila M, Cejalvo JM, González-Farré B, Espinosa-Bravo M, Cruz J, Salvador-Bofill FJ, Guerra JA, Luna Barrera AM, Arumi de Dios M, Esker S, Fan PD, Martínez-Sáez O, Villacampa G, Paré L, Ferrero-Cafiero JM, Villagrasa P, Prat A. Pascual T, et al. Among authors: ferrero cafiero jm. Front Oncol. 2021 Apr 23;11:638482. doi: 10.3389/fonc.2021.638482. eCollection 2021. Front Oncol. 2021. PMID: 33968735 Free PMC article.
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
Antonijoan RM, Ferrero-Cafiero JM, Coimbra J, Puntes M, Martínez-Colomer J, Arévalo MI, Mascaró C, Molinero C, Buesa C, Maes T. Antonijoan RM, et al. Among authors: ferrero cafiero jm. CNS Drugs. 2021 Mar;35(3):331-344. doi: 10.1007/s40263-021-00797-x. Epub 2021 Mar 23. CNS Drugs. 2021. PMID: 33755924 Free PMC article. Clinical Trial.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Pascual T, Cejalvo JM, Oliveira M, Vidal M, Vega E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, la Cruz-Merino L, Juan M, Ferrero-Cafiero JM, Canes J, Gonzalez X, Villagrasa P, Prat A. Pascual T, et al. Among authors: ferrero cafiero jm. Future Oncol. 2020 Aug;16(24):1801-1813. doi: 10.2217/fon-2020-0246. Epub 2020 Jul 7. Future Oncol. 2020. PMID: 32633563